Page 65 - பிரேசிலியன் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Названы даты экзаменов для выпускников школ, не поступающих в вузы
profile.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from profile.ru Daily Mail and Mail on Sunday newspapers.
Народный аристократ СССР
kommersant.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kommersant.ru Daily Mail and Mail on Sunday newspapers.
Почему ковид мешает спать? Врач-сомнолог — о бессоннице и бесполезных снотворных
interfax.by - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from interfax.by Daily Mail and Mail on Sunday newspapers.
The Brazilian National Council for Scientific and Technological Development (CNPq) recently announced a list of research projects selected in a call for proposals to receive R$50 million in funding for COVID-19 research. Of this amount, R$30 million will be drawn from the National Fund for Scientific and Technological Development (FNDCT) for research into treatments, vaccines, diagnostic tests, and the pathogenesis or biological mechanism of the disease. The other R$20 million will be contributed by the Brazilian Ministry of Health for use in projects around prevention, containment and healthcare (
see article). The overwhelming response to the call for projects shows that the scientific community in Brazil is eager to advance research about the disease, more than the government can afford. A total of 2,219 project proposals were submitted. If all were approved, these projects would involve R$1.7 billion in funding, 34 times more than available. An evaluation committee recommended a
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low .
VALNEVAJanuary 25, 2021 GMT
Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 20201. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 20192.